DDInter1628 DDInter1032
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lefamulin
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lefamulin
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Octreotide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Idarubicin
Idarubicin {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Albendazole
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK3
PLK3 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Ruxolitinib {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Idarubicin {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Ruxolitinib (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Ruxolitinib (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Octreotide (Compound) and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Ruxolitinib (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Idarubicin (Compound) and Idarubicin may lead to a major life threatening interaction when taken with Lefamulin
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Albendazole (Compound) and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Ruxolitinib (Compound) binds PLK3 (Gene) and PLK3 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Ruxolitinib (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is downregulated by Idarubicin (Compound) and Idarubicin may lead to a major life threatening interaction when taken with Lefamulin